Evidence mapPaperPMID 37841649Full record

ReviewClinical interventions in aging2023

Management of Glucose-Lowering Therapy in Older Adults with Type 2 Diabetes: Challenges and Opportunities.

Jean Doucet, Pierre Gourdy, Laurent Meyer, Nabil Benabdelmoumene, Isabelle Bourdel-Marchasson

Open access · goldAbstract readReview
In one paragraph

Review in Clinical interventions in aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Article
  8. The Prevalence of Atherosclerotic Cardiovascular Disease in Patients with Type 2 Diabetes in Jordan: The PACT-MEA Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Article
  9. Article
  10. The burden of metabolic diseases in the Arab region, 1990-2021.Therapeutic advances in endocrinology and metabolism · 2025
    Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Jean DoucetDepartment of Polyvalent Internal Medicine, Saint Julien Hospital, Rouen University Hospital, Rouen, France.
Pierre GourdyDepartment of Diabetology, Toulouse University Hospital, Toulouse, France.
Laurent MeyerDepartment of Endocrinology, Diabetes and Nutrition, University Hospital of Strasbourg, Strasbourg, France.
Nabil BenabdelmoumeneDepartment of Internal Medicine and Geriatrics, University Hospital of Marseille, Marseille, France.
Isabelle Bourdel-MarchassonCNRS, CRMSB, UMR 5536, University of Bordeaux, Bordeaux, France.
Assistance Publique Hôpitaux de Marseille · FRCentre National de la Recherche Scientifique · FRHôpital Saint-Julien · FRInserm · FRUniversité de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The population of older adults (≥65 years) with type 2 diabetes mellitus (T2DM) is diverse, encompassing individuals with varying functional capabilities, living arrangements, concomitant medical conditions, and life expectancies. Hence, their categorization into different patient profiles (ie, good health, intermediate health, poor health) may aid in clinical decision-making when establishing glycemic goals and pharmacological treatment strategies. Further granularity in assessing each patient profile through interdisciplinary collaboration may also add precision to therapeutic and monitoring decisions. In this review, we discuss with a multidisciplinary approach how to deliver the best benefit from advanced diabetes therapies and technologies to older adults with T2DM according to each patient profile. There remain however several areas that deserve further research in older adults with T2DM, including the efficacy and safety of continuous glucose monitoring and automated insulin delivery systems, the switch to once-weekly insulin, the effectiveness of multidisciplinary care models, and the use of supported telemedicine and remote blood glucose monitoring in the oldest-old (≥85 years) who particularly require the assistance of others.

Indexed as

Diabetes Mellitus, Type 2AgedAged, 80 and overBlood GlucoseBlood Glucose Self-MonitoringGlucoseHumansHypoglycemic AgentsInsulinBlood GlucoseGlucoseHypoglycemic AgentsInsulinmanagementolder adultspatient profilestype 2 diabetes

Identifiers

PMID37841649
PMCPMC10573466
OpenAlexW4387455404

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.